QUESTO SITO UTILIZZA COOKIE
Con un browser aggiornato, l'esperienza sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.
Si, sono un operatore sanitario
I contenuti presenti nella pagina che segue contengono informazioni rivolte esclusivamente agli OPERATORI SANITARI, in quanto si riferiscono a prodotti rientranti nella categoria dei dispositivi medici che richiedono l’impiego o l’intervento da parte di professionisti del settore medico-sanitario.
Simplicity clears the way to let you decide what's best. Our products are part of our promise to focus all our efforts on helping you seize simplicity. From the simple reliability of the Hancock® II valve to the simple versatility of the Mosaic® valve, consider Medtronic.
Surgical Heart Valve Portfolio (1.51 MB)
Annuloplasty is used to restore an optimal orifice area and shape, provide support, and prevent further annular dilatation. Various techniques are used in mitral reconstruction. Developed in collaboration with the world's most experienced valve repair surgeons, our extensive portfolio of rigid, semi-rigid and flexible repair products gives you an opportunity to select a ring or band for each unique patient need.
Medtronic's tissue valve expertise benefits from more than 40 years of experience, research, and skill, allowing us to provide the world with not only choice, but with advanced features that make a difference in patients' lives. Our third generation of tissue valve technology brings you AOA® tissue treatment, the Physiologic Fixation™ process, and now, the Cinch® Implant System – demonstrating our commitment to innovation.
The latest addition to Medtronic’s tissue valve portfolio, 3f® Aortic Bioprosthesis, is the only pericardial tissue valve designed to function like a native human aortic valve.
Age, calcium metabolism and glutaraldehyde pretreatment all contribute to the failure of tissue valves. AOA treatment is Medtronic's biochemical approach to mitigating calcification in the wall and leaflets of tissue valves. It is distinguished from other tissue treatments by its unique interaction and covalent bonding with the free aldehydes of glutaraldehyde.1
Pressure fixation of valves can compromise the function and durability of the bioprosthesis.1,2,3 The Physiologic Fixation process, used in Medtronic's third generation tissue valves, was developed to address the problem of structural valve deterioration caused by mechanical stress and is designed to maintain native collagen structure and porcine aortic root and leaflet geometry.
The innovative, patented Cinch System, exclusively offered with the Mosaic® and Hancock® II aortic and mitral bioprostheses, draws the stent posts in to provide better visualization and more room for tying behind the stent posts. Suture knots slide easily down the surface of the device and into place. Release the system and the stent posts return to their original position.
Medtronic Open Pivot™ mechanical heart valves bring something fundamentally different to bileaflet valve design. Unlike valves with a conventional cavity pivot hinge design, Medtronic Open Pivot valves have no recesses or cavities where potential thrombogenesis can occur.4,5 In-vitro testing demonstrates that the Medtronic Open Pivot design reduces shear stress and turbulence through the pivot area.6 Clinical results show excellent thrombogenic and hemodynamic performance7,8 and outstanding durability and implantability.7-9 In addition, several patient studies show that Medtronic Open Pivot valves are remarkably quiet.10
The Medtronic Open Pivot™ Aortic Valved Graft (AVG) unites the proven performance of the Open Pivot Heart Valve with leading graft technology for exceptional implantability. This valved conduit has no tapers or pleats, allowing for easy anastomosis anywhere on the graft.
Current techniques and strategies for correction of cardiac anomalies of the RVOT include surgical repair and/or replacement of the pulmonary valve. These techniques include surgical implantation of bioprosthetic conduits or valves, or replacement via transcatheter technologies. A bioprosthetic conduit can consist of woven polyester tubes as supportive housing for glutaraldehyde-fixed porcine or bovine pericardial valves. Other surgeons prefer to implant a non-valved conduit or homograft, or to perform a valvuloplasty, thereby establishing a connection between systemic arteries and the pulmonary artery.
Girardot M-N, Girardot J-M, Torrianni M. In: Gabbay S, Frater RWM, eds. New Horizons and the Future of Heart Valve Bioprostheses: Is Glutaraldehyde a Villain? Austin, TX: Silent Partners, Inc.;1994:41-52.
Christie GW. Anatomy of aortic heart valve leaflets: The influence of glutaraldehyde fixation on function. Eur J Cardiothorac Surg. 1992;6(suppl):S25-33.
Schoen FJ, Levy RJ. Tissue heart valves: Current challenges and future research perspectives. J Biomed Mater Res. 1999;47:439-465.
Kelly SGD, Verdonck PR, Vierendeels JAM, et al. A three-dimensional analysis of flow in the pivot regions of an ATS bileaflet valve. Int J Artif Organs. 1999;22:754-763.
Emery RW, Petersen RJ, Kersten TE, et al. The initial United States experience with the ATS mechanical cardiac valve prosthesis. Heart Surgery Forum. 2001;4(4):346-353.
Dumont K, Vierendeels J, Kaminsky R, van Nooten G, Verdonck P, Bluestein D. Comparison of the hemodynamic and thrombogenic performance of two bileaflet mechanical heart valves using a CFD/FSI model. J Biomech Eng. 2007 Aug;129(4):558-565.
ATS Medical, Inc. Pre-market Approval Application – Summary of Safety and Effectiveness: 2000. Washington D.C.: U.S. Food and Drug Administration; 2000.
Sezai A, Hata M, Niino T, et al. Fifteen years of experience with ATS mechanical heart valve prostheses. J Thorac Cardiovasc Surg. 2010;139:1494-1500.
Van Nooten GJ, Caes F, Francois K, et al. Fifteen years’ single-center experience with the ATS bileaflet valve. J Heart Valve Dis. 2009;18(4):445-452.
Sezai A, Shiono M, Orime Y, et al. Evaluation of valve sound and its effects on ATS prosthetic valves in patient's quality of life. Ann Thorac Surg. 2000;69:507-512.
No clinical data are available that evaluate the long-term impact of AOA® tissue treatment and the Physiologic Fixation process in patients.
Medtronic presents the Streamline® family of temporary sensing and pacing leads. Our engineers have taken the gold standard in temporary pacing leads and improved upon the features that make them easy to use and less traumatic to heart tissue.
Streamline leads integrate more than 50 years of scientific and technological expertise from Medtronic, the world leader in pacing. Designed for temporary pacing and sensing during and after cardiac surgery, Streamline leads are available in either bipolar or unipolar configurations for ventricular or atrial applications in adult or pediatric populations. Streamline leads are the leads you can trust.
Most Streamline temporary pacing leads feature a sutureless fixation coil, which minimizes tissue trauma during lead insertion and removal. Medtronic's discrete electrode technology provides consistent and reliable sensing and pacing. These and other improved features are available in most models.
Medtronic Italia S.p.A. Società soggetta ad attività di direzione e coordinamento da parte di Medtronic Inc.
Cap. soc. € 1.200.000,00 - Registro Imprese N. 281327 Tribunale Milano - R.E.A. N. 1275682 - Cod. Fisc./P.IVA 09238800156
Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano